Top Markets
#1 Helium Helium +56.17%
#2 GEKKO GEKKO +53.94%
#3 ADO Protocol ADO Protocol +38.93%
#4 TENDIES TENDIES +37.05%
#5 Pons Pons +36.07%
#6 StonkBroker StonkBroker +32.23%
#7 Collector Crypt Collector Crypt +30.65%
#8 Prom Prom +28.49%
#9 o1.exchange o1.exchange +22.87%
#10 龙虾 (Lobster) 龙虾 (Lobster) +20.71%
Coin of the day
Helium Helium
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
CARsgen Therapeutics Holdings Limited CARsgen Therapeutics Holdings Limited

CARsgen Therapeutics Holdings Limited

2171
Classificação em ações #9600
CARsgen Therapeutics Holdings Limited, a biopharmaceutical firm founded in... CARsgen Therapeutics Holdings Limited, a biopharmaceutical firm founded in Shanghai, China, in 2014, focuses on the discovery, development, and commercialization of advanced chimeric antigen receptor T (CAR-T) cell therapies. The company's efforts are directed toward treating various hematological malignancies and solid tumors across China and the United States. Its robust pipeline includes several key candidates: CT053, an autologous CAR-T product, is currently in a pivotal Phase II trial in China for relapsed/refractory multiple myeloma. Additionally, CT041, another autologous CAR-T, is undergoing Phase Ib/II clinical trials for advanced gastric/gastroesophageal junction and pancreatic cancers in China, and Phase Ib trials for comparable indications in the U.S. CARsgen is also advancing CT011, an autologous CAR-T candidate, through Phase I for patients with Glypican-3 positive advanced hepatocellular carcinoma, and CT032, an autologous CAR-T, in Phase I/II for B cell Non-Hodgkin's lymphoma in China. Furthermore, its pipeline features AB011, a humanized monoclonal antibody in Phase I for CLDN18.2 positive solid tumors in China, as well as CT017, an autologous Glypican-3-targeted CAR-T for hepatocellular carcinoma, and other promising therapies for solid tumors.
Preço da ação
$1.72
Última sincronização: 2026-08-28
Valor de mercado
$981.92M
Variação (1 dia)
-1.68%
Variação (1 ano)
-41.83%
País
CN
Negociar CARsgen Therapeutics Holdings Limited (2171)

Categoria

Healthcare
Rácio P/B de CARsgen Therapeutics Holdings Limited (2171)
Rácio P/B em 2026 TTM: 0
De acordo com os relatórios financeiros mais recentes e o preço das ações da CARsgen Therapeutics Holdings Limited, o rácio P/B atual (TTM) é 0. No final de 2026, o rácio P/B era 0.
Histórico do rácio P/B da CARsgen Therapeutics Holdings Limited de 2026 a 2026
Rácio P/B no final de cada ano
Ano Rácio P/B Alterar
Não há dados suficientes para as datas fornecidas.
Rácio P/B de empresas semelhantes ou concorrentes
Empresa Rácio P/B Diferença do rácio P/B País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 3.7087 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH